‘A high court judge is to rule on whether a preventive treatment for HIV that charities say is a “game changer” should be funded by the NHS.’
The Guardian, 2nd August 2016
Source: www.guardian.co.uk
‘A high court judge has been asked to overturn an decision on funding for a preventive treatment for HIV that charities say is a “gamechanger”.’
The Guardian, 13th July 2016
Source: www.guardian.co.uk
‘The advertising watchdog has banned a TV ad for Nurofen for misleading viewers with claims it has special painkilling prowess, in a landmark ruling likely to spark a crackdown in the way companies are allowed to market general painkillers.’
The Guardian, 29th June 2016
Source: www.guardian.co.uk
‘After yesterday’s leave vote, the UK government will need to start the process of disentangling the country from the EU. Formal steps to trigger withdrawal under Article 50 of the EU Treaty are currently expected to await Prime Minister David Cameron’s replacement in the coming months, although informal negotiations may begin sooner. What will be the legal impact for innovative businesses?’
Technology Law Blog, 24th June 2016
Source: www.technology-law-blog.co.uk
‘The NHS watchdog NICE has been asked by government to look at the cost of providing an HIV prevention treatment known as Prep.’
BBC News, 7th June 2016
Source: www.bbc.co.uk
‘As part of new legislation, police in England and Wales can use road-side tests to determine drug levels in dangerous drivers.’
The Independent, 1st June 2016
Source: www.independent.co.uk
‘The Specialised Services Commissioning Committee of NHS England has accepted external legal advice and concluded that it does not have the legal power to commission the new HIV treatment, PrEP.’
Local Government Lawyer, 1st June 2016
Source: www.localgovernmentlawyer.co.uk
‘A group of military personnel are seeking damages from the Ministry of Defence over an anti-malarial drug they say has caused mental health problems.’
BBC News, 11th May 2016
Source: www.bbc.co.uk
‘NHS England has been ordered by the High Court to treat a teenager with a severe neurological condition.’
Daily Telegraph, 5th May 2016
Source: www.telegraph.co.uk
‘April 2016 is a month of big changes for people living and working in the UK. A number of new laws and policies are coming into force, affecting just about everyone from public sector workers to dog owners. Here’s what the new laws could mean for you.’
The Independent, 3rd April 2016
Source: www.independent.co.uk
‘Nine pharmacists who sold drugs illegally have been banned from practice, after a BBC investigation led to the “biggest crackdown” in UK pharmaceutical history.’
BBC News, 6th March 2016
Source: www.bbc.co.uk
‘A woman has been awarded £27,000 after a hospital began a Caesarean without giving her adequate pain relief.’
The Independent, 10th February 2016
Source: www.independent.co.uk
‘In accordance with its general obligation of co-operation pursuant to article 111 of Council Directive 2001/83/EC, the Medicines and Healthcare Products Regulatory Agency was lawfully entitled and obliged to supply the European Medicines Agency, pursuant to formal requests under article 8 of Commission Regulation (EC) No 658/2007, with information it had obtained from a marketing authorisation holder.’
WLR Daily, 21st December 2015
Source: www.iclr.co.uk
‘It has been more than half a century since the thalidomide scandal, but Martin Fletcher finds that the victims’ fight for compensation is far from over.’
Daily Telegraph, 7th January 2016
Source: www.telegraph.co.uk
‘Britain’s drug regulators have given the go-ahead for a British American Tobacco (BAT) e-cigarette to be sold as a medicine for quitting smoking, the first such product to be given a drug licence in the UK.’
The Guardian, 4th January 2016
Source: www.guardian.co.uk
‘In Swiss Style Claims: Warner-Lambert Companv Actavis 25 Jan 2015 I explained that Warner-Lambert LLC had a patent for a drug called pregabalin for treating epilepsy and GAD (generalized anxiety disorder). That patent expired in 2013 although the monopoly was extended for a short time by a supplementary protection certificate which has now lapsed. Warner-Lambert discovered a new use for pregabalin in the treatment of neuropathic pain for which it was granted a new patent. Actavis sought the revocation of the new patent on grounds of obviousness and insufficiency and applied for permission to market pregabalin for the treatment of epilepsy and GAD. The case that I discussed in my case note was an unsuccessful attempt by Warner-Lambert to impose conditions on the sale of pregabilin in the UK (see Warner -Lambert Company, LLC v Actavis Group Ptc EHF and others [2015] EWHC 72 (Pat)).’
NIPC Law, 9th December 2015
Source: www.nipclaw.blogspot.co.uk
‘The UK’s advertising watchdog is investigating claims made by the makers of Nurofen after an Australian court ordered the company to step selling several versions of the popular painkiller.’
The Guardian, 15th December 2015
Source: www.guardian.co.uk
‘Two former UN consultants have been jailed by a UK court for receiving bribes to rig contracts worth £66m to supply life-saving drugs to the Democratic Republic of Congo. Guido Bakker, 41, and Sijbrandus Scheffer, 63, took payments totalling £650,000 from a Danish pharmaceutical company called Missionpharma in return for helping them win lucrative contracts.’
The Guardian, 23rd September 2015
Source: www.guardian.co.uk
‘According to drugs.com, pregabalin is an anti-epileptic drug which works by slowing down impulses in the brain that cause seizures. A European patent for the drug was granted to Warner-Lambert Co, LLC (“Warner-Lambert”)(now a subsidiary of Pfizer Inc.) under EP number 0 641 330. That patent expired on 17 May 2013 but was extended by a supplementary protection certificate (“SPC”) until 17 May 2018. That SPC was allowed to lapse on 14 Oct 2013 and Warner-Lambert’s data exclusivity in respect of the data used to obtain the marketing authorisation for prehabalin expired on 8 July 2014. Since then anybody has been free to make, import or sell pregabalin for treating epilepsy and generalized anxiety disorder in the United Kingdom and several companies including some of the parties to these proceedings have done just that.’
NIPC Law, 18th September 2015
Source: www.nipclaw.blogspot.co.uk
© Inner Temple Library 2024